AxoGen, Inc. (NASDAQ:AXGN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

AxoGen, Inc. (NASDAQ:AXGN) has earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $50.4444.

Several research analysts recently commented on AXGN shares. Wells Fargo & Company boosted their target price on AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Sunday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AxoGen in a research report on Friday, May 29th. Jefferies Financial Group reaffirmed a “buy” rating and set a $55.00 price objective on shares of AxoGen in a research report on Wednesday. Finally, Lake Street Capital increased their target price on AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, April 23rd.

AxoGen Trading Up 4.9%

NASDAQ:AXGN traded up $2.04 during trading hours on Thursday, reaching $43.41. 276,306 shares of the stock were exchanged, compared to its average volume of 1,116,370. The business has a 50-day moving average of $42.10 and a two-hundred day moving average of $37.28. AxoGen has a twelve month low of $12.39 and a twelve month high of $46.95. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of -67.52 and a beta of 1.09. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08.

AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, meeting the consensus estimate of $0.12. The company had revenue of $69.73 million during the quarter, compared to the consensus estimate of $67.10 million. AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%. On average, equities analysts predict that AxoGen will post -0.37 EPS for the current year.

Key Stories Impacting AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: AxoGen reported second-quarter revenue of $69.73 million, above the $67.10 million analyst estimate. Earnings were $0.12 per share; this matched the broader consensus cited by MarketBeat and exceeded the $0.09 Zacks consensus estimate. AxoGen Second Quarter 2026 Financial Results
• Positive Sentiment: The earnings coverage highlighted continued strong revenue growth, supporting the investment case for AxoGen’s peripheral nerve repair products and helping drive the favorable stock reaction. AxoGen Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Management updated its fiscal 2026 earnings guidance, but the available report does not provide the revised figures, limiting the ability to assess whether the outlook improved or weakened. AxoGen Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the revenue and adjusted-EPS performance, AxoGen continues to face margin pressure. The company reported a negative net margin of 13.21% and negative return on equity, while analysts expect a full-year loss of approximately $0.37 per share. AxoGen Q2 2026 Earnings

Insiders Place Their Bets

In other news, Director Kathy Johnson Weiler sold 16,344 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $44.09, for a total transaction of $720,606.96. Following the completion of the transaction, the director directly owned 16,344 shares of the company’s stock, valued at approximately $720,606.96. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Johnson sold 11,050 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $43.26, for a total value of $478,023.00. Following the completion of the transaction, the director owned 11,050 shares in the company, valued at approximately $478,023. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 29,041 shares of company stock valued at $1,268,792 in the last ninety days. Insiders own 2.44% of the company’s stock.

Hedge Funds Weigh In On AxoGen

Several hedge funds have recently added to or reduced their stakes in AXGN. MFG Wealth Management Inc. acquired a new position in shares of AxoGen in the 2nd quarter valued at $1,195,000. California State Teachers Retirement System boosted its stake in AxoGen by 51.9% in the first quarter. California State Teachers Retirement System now owns 59,129 shares of the medical equipment provider’s stock valued at $1,959,000 after acquiring an additional 20,203 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of AxoGen by 66.4% during the first quarter. The Manufacturers Life Insurance Company now owns 22,166 shares of the medical equipment provider’s stock worth $734,000 after purchasing an additional 8,844 shares during the last quarter. SummitTX Capital L.P. purchased a new position in shares of AxoGen during the first quarter worth about $7,769,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of AxoGen during the first quarter worth about $3,847,000. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.